Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michelson

Showing results (191-200 of 252) with videos related to

Pageof 26
Sort By:
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialJohn J V McMurray, Jan Ostergren, Karl Swedberg, et al.
Journal of the American College of Cardiology|October 24, 2002
The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective studyAgha W Haider, Peter W F Wilson, Martin G Larson, et al.
Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Lancet (London, England)|December 13, 2005
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trialBradi B Granger, Karl Swedberg, Inger Ekman, et al.
The American Journal of Cardiology|January 27, 2009
Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphologyZeeshan Syed, Benjamin M Scirica, Satishkumar Mohanavelu, et al.
Journal of the American College of Cardiology|February 1, 1988
Differential effects of procainamide, lidocaine and acetylstrophanthidin on body surface potentials and epicardial conduction in dogs with chronic myocardial infarctionC D de Langen, R F Hanich, E L Michelson, et al.
Heart Disease (Hagerstown, Md.)|November 27, 2001
Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study GroupA H Gradman, A Lewin, B T Bowling, et al.
The American Journal of Cardiology|March 16, 2001
Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study InvestigatorsR A Kloner, M Weinberger, J L Pool, et al.
Pageof 26

Showing results (191-200 of 252) with videos related to

Sort By:
Pageof 26
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialJohn J V McMurray, Jan Ostergren, Karl Swedberg, et al.
Journal of the American College of Cardiology|October 24, 2002
The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective studyAgha W Haider, Peter W F Wilson, Martin G Larson, et al.
Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Lancet (London, England)|December 13, 2005
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trialBradi B Granger, Karl Swedberg, Inger Ekman, et al.
The American Journal of Cardiology|January 27, 2009
Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphologyZeeshan Syed, Benjamin M Scirica, Satishkumar Mohanavelu, et al.
Journal of the American College of Cardiology|February 1, 1988
Differential effects of procainamide, lidocaine and acetylstrophanthidin on body surface potentials and epicardial conduction in dogs with chronic myocardial infarctionC D de Langen, R F Hanich, E L Michelson, et al.
Heart Disease (Hagerstown, Md.)|November 27, 2001
Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study GroupA H Gradman, A Lewin, B T Bowling, et al.
The American Journal of Cardiology|March 16, 2001
Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study InvestigatorsR A Kloner, M Weinberger, J L Pool, et al.
Pageof 26